AU2016261707A8 - Use of cannabis to treat fibromyalgia, methods and compositions thereof - Google Patents

Use of cannabis to treat fibromyalgia, methods and compositions thereof Download PDF

Info

Publication number
AU2016261707A8
AU2016261707A8 AU2016261707A AU2016261707A AU2016261707A8 AU 2016261707 A8 AU2016261707 A8 AU 2016261707A8 AU 2016261707 A AU2016261707 A AU 2016261707A AU 2016261707 A AU2016261707 A AU 2016261707A AU 2016261707 A8 AU2016261707 A8 AU 2016261707A8
Authority
AU
Australia
Prior art keywords
cannabis
methods
compositions
treat fibromyalgia
fibromyalgia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016261707A
Other versions
AU2016261707A1 (en
Inventor
Yehuda Baruch
Alon SINAI
Ziv TURNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
One World Cannabis Ltd
Original Assignee
One World Cannabis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by One World Cannabis Ltd filed Critical One World Cannabis Ltd
Publication of AU2016261707A1 publication Critical patent/AU2016261707A1/en
Publication of AU2016261707A8 publication Critical patent/AU2016261707A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a composition comprising cannabis natural extract, or synthetic cannabinoids, for use in treating a subject suffering from fibromyalgia. The present invention further discloses methods and uses of the aforementioned composition.
AU2016261707A 2015-05-13 2016-05-11 Use of cannabis to treat fibromyalgia, methods and compositions thereof Abandoned AU2016261707A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562160609P 2015-05-13 2015-05-13
US62/160,609 2015-05-13
PCT/IL2016/050498 WO2016181394A1 (en) 2015-05-13 2016-05-11 Use of cannabis to treat fibromyalgia, methods and compositions thereof

Publications (2)

Publication Number Publication Date
AU2016261707A1 AU2016261707A1 (en) 2017-12-07
AU2016261707A8 true AU2016261707A8 (en) 2018-01-04

Family

ID=57247955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016261707A Abandoned AU2016261707A1 (en) 2015-05-13 2016-05-11 Use of cannabis to treat fibromyalgia, methods and compositions thereof

Country Status (6)

Country Link
US (2) US20180116998A1 (en)
EP (1) EP3294289A4 (en)
AU (1) AU2016261707A1 (en)
CA (1) CA2985969A1 (en)
IL (1) IL255615A (en)
WO (1) WO2016181394A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018002926A1 (en) 2016-06-28 2018-01-04 Seach Sarid Ltd. A dosage form for vaporization and smoking
CN108079305A (en) * 2016-11-23 2018-05-29 汉义生物科技（北京）有限公司 The medical composition and its use of cannabidiol and tricyclic antidepressant
EP3488220A4 (en) * 2016-11-29 2020-03-04 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and gabapentin
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2019041239A1 (en) * 2017-08-31 2019-03-07 汉义生物科技（北京）有限公司 Uses of cannabidiol in preparation of drugs for resisting against influenza
WO2019056128A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
AU2019251357B2 (en) 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
CN110575447B (en) * 2018-06-07 2022-11-29 汉义生物科技（北京）有限公司 Pharmaceutical composition for preventing and treating diabetes and application thereof
AU2018426503A1 (en) * 2018-06-07 2021-01-21 Hanyi Bio-Technology Company Ltd. Pharmaceutical composition for preventing diabetes and use thereof
CA3103938A1 (en) * 2018-06-15 2019-12-19 California Cannabinoids Compositions and methods for treatment of narcolepsy and related disorders
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. Synthesis of cannabigerol
EP4272731A3 (en) 2018-12-11 2024-02-14 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
WO2020220092A1 (en) * 2019-05-01 2020-11-05 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
IL292775A (en) * 2019-11-08 2022-07-01 Vella Bioscience Inc Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
JP2023504756A (en) 2019-12-09 2023-02-06 ニコベンチャーズ トレーディング リミテッド Oral products containing cannabinoids
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
EP3160451B1 (en) * 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same

Also Published As

Publication number Publication date
WO2016181394A1 (en) 2016-11-17
US20200129471A1 (en) 2020-04-30
AU2016261707A1 (en) 2017-12-07
EP3294289A1 (en) 2018-03-21
EP3294289A4 (en) 2019-01-02
IL255615A (en) 2018-01-31
CA2985969A1 (en) 2016-11-17
US20180116998A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
AU2016261707A8 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
HK1246663A1 (en) Methods of purifying cannabinoids, compositions and kits thereof
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
MX2019003735A (en) Dilutable formulations of cannabinoids and processes for their preparation.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
AU2016263598A8 (en) Methods and kits for treating depression
MX2018006632A (en) Bicyclic inhibitors of pad4.
MX2018000590A (en) Antibody molecules which bind cd79.
GEP20197049B (en) Compositions and methods for treating surface wounds
MX2018016057A (en) Compositions and methods for treating cardiovascular disease.
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
MX2018000715A (en) Methods for treating cancer using apilimod.
WO2015142500A3 (en) Compositions and methods for treating addiction
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017008390A (en) Alkoxysilane-functionalized and allophanate-functionalized urethanes.
MX2020006596A (en) Hydroxyisoxazolines and derivatives thereof.
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2015008310A (en) Method of treatment of hypoxia inducible factor (hif)-related conditions.
MX2022015456A (en) Maca compositions and methods of use.
MX2018007468A (en) Collagen 7 compositions and methods of using the same.
MX2017006807A (en) Titled extracts of cynara scolymus and uses thereof.
WO2016046759A3 (en) Compositions and methods for treating friedreich's ataxia
MX2017006548A (en) 2-octylcyclopropyl-1-carboxylic acid and the isomers thereof, and uses of same.
MX2017008655A (en) Jasmonate derivatives and compositions thereof.

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 48 , PAGE(S) 6979 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ONE WORLD CANNABIS LTD, APPLICATION NO. 2016261707, UNDER INID (72) ADD CO-INVENTOR BARUCH, YEHUDA

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application